Project Grant R01HL178575
Award Date 8/1/26
Completion Date 4/30/30
Dollars Obligated $578K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Albany, NY 12208, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of Washington $814,385 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of secreted phospholipase A2 group X (sPLA2-X) in airway physiology and asthma pathogenesis. The research examines how sPLA2-X, an enzyme secreted into airways and elevated in asthma patients, contributes to airway inflammation and hyperresponsiveness. The work combines human localization studies...
- The National Heart, Lung, and Blood Institute awarded $777,498 to the University of North Carolina at Chapel Hill on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on multiscale integration of mucin secretion and ion transport rates in asthmatic mucus plug formation and persistence. The research tests the applicability of a biophysical paradigm called the "two-gel" paradigm to asthma pathogenesis, examining whether asthma mucus...
- The National Heart, Lung, and Blood Institute awarded Albany Medical College $1,634,428 on June 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate inflammation-resolution mechanisms in endothelial cells as they relate to atherosclerosis progression and regression. The project addresses a gap in understanding how pro-resolving mediators—including specialized pro-resolving mediators derived from omega-3 fatty acids (such as resolvins), suppressor of cytokine...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $868,048 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a longitudinal study of airway dysanapsis and early-life risk factors for chronic obstructive pulmonary disease. The research, titled Predictors of Airway Dysanapsis in Early Life (PADEL), leverages eight longitudinal birth cohorts to examine relationships between early-life exposures...
- The National Heart, Lung, and Blood Institute awarded The University of Iowa $599,466 on August 19, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund research examining the cellular and molecular mechanisms driving submucosal gland hypertrophy in chronic lung diseases including asthma, COPD, and cystic fibrosis. The funded research will identify fundamental pathways responsible for pathological gland enlargement by defining key cell-cell interactions and signaling...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $3,205,321 on August 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the genetic and molecular mechanisms of prostaglandin E2 (PGE2)-EP4-induced goblet cell metaplasia in asthma. The project combines biophysical, cellular, molecular, and genetic analyses to determine how EP4 receptor activation promotes goblet cell hyperplasia in airway...
- The National Heart, Lung, and Blood Institute awarded Albert Einstein College of Medicine $1,601,624 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a cluster randomized controlled trial evaluating PRAGMATIC-S, a technology-enabled care coordination system linking primary care clinics and school-based asthma programs for urban children with persistent or uncontrolled asthma. The award funds development and testing of an innovative interface...
- The National Heart, Lung, and Blood Institute awarded $448,250 to The Research Foundation For The State University Of New York on May 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and evaluate a lung-targeted immunomodulatory messenger RNA therapy for acute respiratory distress syndrome. The award funds development of an IL-10 mRNA therapeutic delivered via sulfonium lipid nanoparticles, a novel lung-targeting technology designed to suppress...
- The National Heart, Lung, and Blood Institute awarded Albany Medical College $586,474 under CFDA 93.837 (Cardiovascular Diseases Research) on June 15, 2026, to investigate lipolytic sterol signaling mechanisms in foam cell modulation and atherosclerosis prevention. The project targets lipid droplet-associated hydrolase (LDAH) as a regulator of adaptive responses to lipid overload in atherosclerotic lesions. Research will examine how LDAH mobilizes sterol stores within cytoplasmic lipid...
- The National Heart, Lung, and Blood Institute awarded The Feinstein Institutes for Medical Research $586,866 on May 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the protective role of B-1a cells in acute lung injury and to evaluate a novel therapeutic compound. The project examines the mechanisms by which B-1a cells mitigate acute lung injury and acute respiratory distress syndrome, conditions frequently triggered by sepsis or ischemia-reperfusion...